Condition
Acneiform Eruptions
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 4 (1)
Trial Status
Unknown2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04697069Phase 2TerminatedPrimary
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
NCT05919810Not ApplicableCompleted
The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne
NCT05120362Not ApplicableUnknownPrimary
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash
NCT04864717Phase 4UnknownPrimary
Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI
Showing all 4 trials